Because of the cooperative nature of WT and mutant EZH2, both forms are good drug targets and EZH2 inhibitors are effective against mutant DLBCL in vivo (158,159), leading to FDA approval of the EZH2 inhibitor tazemetostat for use in patients. Here, EZH2 is linked to diffuse large B-cell lymphoma.